RC220 MYC-silencing data to be presented FCS 26 conference
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura RC220 MYC-silencing data to
be presented at the 2026 Frontiers in
Cancer Science Conference
§ Poster presentation accepted for the Frontiers in Cancer Science 2026 (FCS) Conference to be
held in Singapore, 11-13 November 2026
§ Presentation reveals preclinical data showing that (E,E)-bisantrene is the active isomer stabilising
the G-quadruplex (G4) DNA region found in the MYC gene promoter leading to MYC suppression
§ Results support the MYC-driven mechanism of action of (E,E)-bisantrene and use of RC220 in the
EMILI, HARNESS and CPACS clinical programs
8 September 2026
Racura Oncology Limited (“Racura” or the “Company”) is pleased to announce that it has been selected to
present at the 2026 Frontiers in Cancer Science (FCS) Conference, held in partnership with the American
Association for Cancer Research (AACR), in Singapore from 11-13 November 2026. The FCS presentation
describes results from preclinical studies undertaken by Racura scientists that have established
(E,E)-bisantrene is the active bisantrene isomer stabilising the G-quadruplex (G4) region found in the
promoter region of the MYC gene, leading to reduced MYC gene expression and MYC activity.
The accepted abstract entitled “Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex
Binding and c-MYC Silencing” is attached to this announcement and will be later published in the AACR
peer-reviewed journal, Cancer Research.
Racura Oncology CEO and Managing Director, Dr Daniel Tillett commented: “These results reinforce our
focus on (E,E)-bisantrene and underpin the clinical development strategy for RC220. Confirming (E,E)-
bisantrene as the active isomer driving MYC G4 stabilisation and MYC silencing provides important
mechanistic support for our anthracycline cardioprotection, EGFR-mutant non-small cell lung cancer and
acute myeloid leukaemia clinical programs. We are pleased this work has been accepted for FCS 2026, a
respected international cancer science conference held in partnership with AACR.”
Importance of MYC & G4-DNA in cancer
The MYC protein controls the expression of many cancer-related genes, including those involved in cell
growth, differentiation, survival, metabolic reprogramming, anticancer therapy resistance, and immune
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
surveillance.1
MYC is dysregulated in up to 70% of all cancers, but is widely regarded as undruggable by
the pharmaceutical industry.2
The MYC gene promoter contains a G4 DNA structural region known to
suppress MYC expression when stabilised by specific small molecule binders.3
Data revealing (E,E)-
bisantrene can reduce MYC gene expression via G4 DNA binding and stabilisation was presented at the
2026 AACR Annual Meeting (ASX Announcement: 22 April 2026).
The data to be presented at the FCS conference identifies (E,E)-bisantrene as the active isomer, with the
light-induced (E,Z)-isomer showing significantly less G4 stabilisation, MYC silencing, and anticancer
activity than the (E,E)-isomer.
IP significance
The results presented at the FCS conference support the use of pure (E,E)-bisantrene in the RC220
formulation and strengthen the Company’s patent filings covering protection of (E,E)-bisantrene from light-
induced photoisomerisation, manufacture and formulation of pure (E,E)-bisantrene, and associated
composition of matter claims on (E,E)-bisantrene, (E,Z)-bisantrene and various isomer mixtures.
References
1. González-Larreategui, Í., Valdés-Bango Martín, M., Casacuberta-Serra, S. and Soucek, L. (2026) ‘MYC at the tumor–
immune interface: mechanisms of immune escape and immunotherapy resistance’, Frontiers in Immunology, 17,
1738440.
2. Llombart, V. and Mansour, M.R. (2022) ‘Therapeutic targeting of “undruggable” MYC’, eBioMedicine, 75, 103756.
3. Siddiqui-Jain, A., Grand, C.L., Bearss, D.J. and Hurley, L.H. (2002) ‘Direct evidence for a G-quadruplex in a promoter
region and its targeting with a small molecule to repress c-MYC transcription’, Proceedings of the National Academy of
Sciences of the United States of America, 99(18), pp. 11593–11598.
-ENDS-
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that
primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer
gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer
patients and has a well-characterised safety profile. Racura’s discoveries have supported composition-of-
matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet
need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI
Phase 3 trial in acute myeloid leukaemia, the HARNESS Phase 1a/b trial in combination with osimertinib
for EGFR-mutated non-small cell lung cancer, and the CPACS Phase 1a/b trial in combination with
doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer
activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center,
Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and the
University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential
commercial merger and acquisition opportunities to accelerate global patient access to RC220.
Learn more at www.racuraoncology.com.
For questions about this announcement or previous Racura Oncology announcements, please visit our
Interactive Announcements page.
Racura encourages our investors to go paperless by registering their email details with the Company’s
share registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 4
Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex
Binding and c-MYC Silencing
Emily Ryan1,2
, Peter Cuthbertson1
, Chelsea Penney1
, Nehad S. El Salamouni2
, Qiang Zhu2
, Haibo Yu2
, Sumit
Sahni1
, Daniel Tillett1
, Michael J. Kelso1
1
Racura Oncology Ltd, Sydney, Australia
2
University of Wollongong, Wollongong, Australia
Background: (E,E)-bisantrene consists of an anthracene core with identical (E)-hydrazone substituents at
the 9- and 10-positions. It can stabilize G-quadruplex (G4) DNA structures leading to silencing of c-MYC
gene expression. In solution, visible light converts (E,E)-bisantrene into (E,E)/(E,Z)/(Z,Z) mixtures, raising
the possibility that photoisomerization compromises G4-directed activity and anticancer activity. We
compared pure (E,E)-bisantrene with mixtures containing increasing (E,Z)- and (Z,Z)-bisantrene for effects
on c-MYC promoter G4 stabilization, c-MYC expression, and cancer-cell viability.
Methods: (E,E)-bisantrene solutions were exposed to blue LED light to generate (E,E)/(E,Z)/(Z,Z) mixtures,
which were quantified by HPLC. c-MYC promoter G4 binding and stabilization were measured by circular
dichroism spectroscopy. Molecular dynamics simulations estimated isomer-specific G4 binding energies,
and c-MYC gene/protein expression and viability were assessed across cancer cell lines.
Results: Blue LED light exposure progressively increased (E,Z)- and (Z,Z)-bisantrene and depleted (E,E)-
bisantrene. Depletion of (E,E)-bisantrene reduced c-MYC promoter G4 stabilization, c-MYC gene/protein
suppression, and cancer-cell growth inhibition. Molecular dynamics simulations supported more favorable
G4 binding by (E,E)- than (E,Z)-bisantrene.
Conclusion: (E,E)-bisantrene is the active isomer. Photoisomerization to (E,Z)- and (Z,Z)-bisantrene
weakens c-MYC G4 binding/stabilization, reduces c-MYC silencing, and diminishes anticancer activity,
supporting light protection and clinical use of pure (E,E)-bisantrene. These findings indicate that
formulation, storage, and handling conditions that avoid light exposure to preserve the (E,E)-isomer are
important for maintaining therapeutic potency in clinical settings.
Share your feedback
Discover